Read by QxMD icon Read

Short stature rct

Donghun Lee, Sun Haeng Lee, Jungbin Song, Hee-Jung Jee, Sung Ho Cha, Gyu Tae Chang
HT042 is a standardized functional food ingredient approved by Korean Food and Drug Administration with a claim 'HT042 can help height growth of children'. We aimed to evaluate the safety and efficacy of HT042 on height growth in children with mild short stature. A multicenter, randomized, double-blind, placebo-controlled parallel study was performed on children aged 6-8 years with height ranked below the 25th percentile. In 129 children, height gain was significantly higher in HT042 group than placebo group after 24 weeks (mean difference, 0...
January 2018: Phytotherapy Research: PTR
Bireshwar Sinha, Sunita Taneja, Ranadip Chowdhury, Sarmila Mazumder, Temsunaro Rongsen-Chandola, Ravi Prakash Upadhyay, Jose Martines, Nita Bhandari, Maharaj Kishan Bhan
Low-birthweight (LBW) infants are at an increased risk of stunting and poor linear growth. The risk might be additionally higher in these infants when born to short mothers. However, this hypothesis has been less explored. The objective of this secondary data analysis was to determine the risk of linear growth faltering and difference in linear growth velocity in LBW infants born to short mothers (<150 cm) compared to those born to mothers with height ≥150 cm during the first year of life. This analysis uses data from a community-based randomized controlled trial of 2,052 hospital-born term infants with birthweight ≤2,500g from urban low-middle socioeconomic neighbourhoods in Delhi, India...
January 2018: Maternal & Child Nutrition
Matti Hero
Reports published in the 1990s of men with estrogen deficiency caused by defective aromatase or estrogen resistance due to a defective estrogen receptor α confirmed the crucial role of estrogen in bone maturation, closure of the epiphyses and cessation of statural growth. Based on these findings, it became reasonable to postulate that selective inhibition of estrogen synthesis with aromatase inhibitors could increase adult height by delaying bone maturation and prolonging the period of growth in males. To date, aromatase inhibitors have been employed in rare pediatric conditions associated with sex steroid excess, and in randomized controlled trials involving boys with short stature and/or constitutional delay of puberty...
2016: Endocrine Development
M Gardner, M L Boshart, C E Yeguez, K M Desai, D E Sandberg
CONTEXT: Two often cited assumptions for treating children with GH are that short stature (SS), as an isolated physical characteristic, is associated with psychosocial morbidity and that GH treatment may increase height and improve psychological adjustment. Findings across studies regarding the psychological consequences associated with GH management of children with SS are variable and frequently contradictory. The purpose of this systematic review is to evaluate the degree to which any conclusions about the relative risks or benefits of GH treatment on psychological outcomes can be made based on the published literature...
January 2016: Journal of Clinical Endocrinology and Metabolism
Niamh McGrath, Michael J O'Grady
BACKGROUND: As a result of the essential role of oestrogens in epiphyseal closure, aromatase inhibitors have been trialled as an intervention to improve height outcomes in male children and adolescents by inhibiting the conversion of testosterone to oestradiol. OBJECTIVES: To assess the effects of aromatase inhibitors in male children and adolescents with short stature. SEARCH METHODS: To identify relevant trials, we searched the Cochrane Library (2014, Issue 7), MEDLINE, EMBASE, and the World Health Organization (WHO) ICTRP trial register from their inception until August 2014...
October 8, 2015: Cochrane Database of Systematic Reviews
Nicole M Sheanon, Philippe F Backeljauw
Turner syndrome is a chromosomal abnormality in which there is complete or partial absence of the X chromosome. Turner syndrome effects 1 in every 2000 live births. Short stature is a cardinal feature of Turner Syndrome and the standard treatment is recombinant human growth hormone. When growth hormone is started at an early age a normal adult height can be achieved. With delayed diagnosis young women with Turner Syndrome may not reach a normal height. Adjuvant therapy with oxandrolone is used but there is no consensus on the optimal timing of treatment, the duration of treatment and the long term adverse effects of treatment...
2015: International Journal of Pediatric Endocrinology
Sang-Heon Song, Sang-Gyun Kim, Sung-Eun Kim, Hae-Ryong Song
The aim of the present study was to compare the radiographic and clinical outcomes of DBM injection and conventional treatment during tibial lengthening over an intramedullary nail in adult patients with short stature. Twenty-nine patients were randomized to receive DBM injection (n = 14) or conventional treatment without any injection (n = 15) and evaluated. The outcome was measured on the basis of the pixel value ratio (PVR) in the digital radiographs during the consolidation period; healing index; clinical assessment; and the rate of complications...
2015: BioMed Research International
Zoran Milanović, Goran Sporiš, Nebojsa Trajković, Damir Sekulić, Nic James, Goran Vučković
The aim of this study was to determine the effects of a 12 week speed, agility and quickness (SAQ) training program on speed and flexibility in young soccer players. One hundred and thirty-two soccer players were randomly assigned to experimental (EG; n=66, mean±SD: age: 18.5±0.4 years (range 17-19 years); body mass: 71.30±5.93 kg; stature: 177.2±6.5 cm) and control groups (CG; n=66, mean±SD: age: 18.6±0.6 years (range 17-19 years); body mass: 70.63±4.87 kg; stature: 175.9±5.7 cm). The experimental group performed SAQ training whilst the control group undertook straight-line sprint training matched for volume and duration...
December 2014: Human Movement Science
Kenji Ishikura, Norishige Yoshikawa, Hitoshi Nakazato, Satoshi Sasaki, Koichi Nakanishi, Takeshi Matsuyama, Shuichi Ito, Yuko Hamasaki, Nahoko Yata, Takashi Ando, Kazumoto Iijima, Masataka Honda
BACKGROUND: To investigate the long-term outcome in children with frequently relapsing nephrotic syndrome (FRNS) we conducted a follow-up of a previous randomized controlled trial (RCT) 10 years after the initiation of the treatment protocol. METHODS: We previously conducted an RCT on the efficacy of cyclosporine for treating children with FRNS. After 2 years of treatment, a recommended a management protocol of steroids, and immunosuppressants was provided. RESULTS: Valid information was available for 46 of the 56 patients (82...
March 2015: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
T C J Sas, E J Gault, M Zeger Bardsley, L A Menke, K Freriks, R J Perry, B J Otten, S M P F de Muinck Keizer-Schrama, H Timmers, J M Wit, J L Ross, M D C Donaldson
There has been no consensus regarding the efficacy and safety of oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS), the optimal age of starting this treatment, or the optimal dose. This collaborative venture between Dutch, UK and US centers is intended to give a summary of the data from three recently published randomized, placebo-controlled, double-blind studies on the effects of Ox. The published papers from these studies were reviewed within the group of authors to reach consensus about the recommendations...
2014: Hormone Research in Pædiatrics
Pinchas Cohen, Wayne Weng, Alan D Rogol, Ron G Rosenfeld, Anne-Marie Kappelgaard, John Germak
CONTEXT AND OBJECTIVE: Titrating the dosage of growth hormone (GH) to serum levels of insulin-like growth factor-I (IGF-I) is a feasible treatment strategy in children with GH deficiency (GHD) and idiopathic short stature (ISS). The objective was to assess the dose-sparing effect and theoretical safety of IGF-I-based GH therapy. DESIGN, SETTING AND PATIENTS: This was a post hoc analysis of a previously described 2-year, multicenter, open-label, randomized, outpatient, controlled clinical trial in 172 prepubertal short children [age 7·5 ± 2·4 years; height standard deviation score (HSDS) -2·64 ± 0·61] classified by baseline peak GH levels as GHD (<7 ng/ml) or ISS (≥7 ng/ml)...
July 2014: Clinical Endocrinology
Kim Freriks, Theo C J Sas, Maaike A F Traas, Romana T Netea-Maier, Martin den Heijer, Ad R M M Hermus, Jan M Wit, Janiëlle A E M van Alfen-van der Velden, Barto J Otten, Sabine M P F de Muinck Keizer-Schrama, Martin Gotthardt, Philippe H Dejonckere, Gladys R J Zandwijken, Leonie A Menke, Henri J L M Timmers
OBJECTIVE: Short stature is a prominent feature of Turner syndrome (TS), which is partially overcome by GH treatment. We have previously reported the results of a trial on the effect of oxandrolone (Ox) in girls with TS. Ox in a dose of 0.03 mg/kg per day (Ox 0.03) significantly increased adult height gain, whereas Ox mg/kg per day (0.06) did not, at the cost of deceleration of breast development and mild virilization. The aim of this follow-up study in adult participants of the pediatric trial was to investigate the long-term effects of previous Ox treatment...
January 2013: European Journal of Endocrinology
Michael B Ranke, Anders Lindberg
Many children with idiopathic short stature (ISS) remain short as adults. Height can be improved permanently by growth hormone (GH) treatment, as in children with Turner syndrome or born small for gestational age. Although GH treatment for ISS is an approved indication in the United States, there is ongoing controversy in Europe about approving GH treatment for this indication as well as determining the optimal mode of treatment. In addition to data from randomized controlled trials, data from pharmacoepidemiological surveys such as the Pfizer International Growth Study Database (KIGS) have provided substantial information about the short-term and long-term effects of GH on growth and adult height in children with ISS...
2011: Hormone Research in Pædiatrics
Jovanna Dahlgren
The few studies that have evaluated the long-term height outcomes following growth hormone (GH) treatment in children with idiopathic short stature (ISS) have shown a growth response to GH treatment similar to that in GH-deficient children. A literature search of all randomized and nonrandomized studies of GH treatment in children with ISS from prepubertal years to adult height or near-adult height published over the last 10 years identified six publications (none was a classic meta-analysis). Several studies showed a dose-dependent response in height outcome...
2011: Hormone Research in Pædiatrics
Annalisa Deodati, Emanuela Peschiaroli, Stefano Cianfarani
Recombinant human growth hormone (GH) has been used to increase growth and adult height in children with idiopathic short stature (ISS) despite the lack of definitive, long-term studies of efficacy. Our aim was to systematically review all randomized controlled trials (RCTs) of GH use in children with ISS.We performeda formal search of the Cochrane Central Register of Controlled Trials, Medline and the bibliographic references from all retrieved articles describing such trials up to August 2009. Three long-term RCTs conducted to the achievement of adult height were identified...
2011: Hormone Research in Pædiatrics
Annalisa Deodati, Stefano Cianfarani
OBJECTIVE: To systematically determine the impact of growth hormone therapy on adult height of children with idiopathic short stature. DESIGN: Systematic review. DATA SOURCES: Cochrane Central Register of Controlled Trials, Medline, and the bibliographic references from retrieved articles of randomised and non-randomised controlled trials from 1985 to April 2010. DATA EXTRACTION: Height in adulthood (standard deviation score) and overall gain in height (SD score) from baseline measurement in childhood...
March 11, 2011: BMJ: British Medical Journal
Olivia J Phung, Craig I Coleman, Erica L Baker, Jennifer M Scholle, Jennifer E Girotto, Sagar S Makanji, Wendy T Chen, Ripple Talati, Jeffrey Kluger, C Michael White
CONTEXT: Recombinant human growth hormone (rhGH) improves growth in patients with growth hormone deficiency or idiopathic short stature. Its role in patients with cystic fibrosis (CF) is unclear. OBJECTIVE: To review the effectiveness of rhGH in the treatment of patients with CF. METHODS: Medline and the Cochrane Central Register of Controlled Trials were searched from the earliest date through April 2010. Randomized controlled trials, observational studies, systematic reviews/meta-analyses, or case reports were included if rhGH therapy was administered to patients with CF and data on prespecified harms, intermediate outcomes, or final health outcomes were reported...
November 2010: Pediatrics
Jane Loftus, Rebecca Heatley, Claire Walsh, Paul Dimitri
Genotropin (somatropin) is licensed for the treatment of children with growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, chronic renal insufficiency and in children born small for gestational age. This systematic review (SR) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children. Search terms were used to search seven databases, including Medline and Embase, for English language studies...
June 2010: Journal of Pediatric Endocrinology & Metabolism: JPEM
Torsten Christensen, Andrew Buckland, Anthony Bentley, Christian Djurhuus, Rachael Baker-Searle
BACKGROUND: Short children born small for gestational age (SGA) may be at increased risk for long-term morbidity and reduced health-related quality of life (HRQoL) due to their short stature. Normalization of height in childhood and adolescence is possible in such children via the use of the recombinant human growth hormone somatropin. OBJECTIVE: The aim of this study was to determine whether somatropin was a cost-effective treatment option in short children born SGA...
June 2010: Clinical Therapeutics
Tuula A Paajanen, Niku K J Oksala, Pekka Kuukasjärvi, Pekka J Karhunen
AIMS: The aim of this study was to assess the relationship between short stature and coronary heart disease (CHD) morbidity and mortality. METHODS AND RESULTS: We performed a systematic search from MEDLINE, PREMEDLINE, and All EBM Reviews as well as from a reference list of relevant articles. We used SPICO (Study design, Patient, Intervention, Control-intervention, Outcome) criteria. The methodological quality of studies was analysed by modified Borghoust criteria...
July 2010: European Heart Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"